Copyright
©The Author(s) 2024.
World J Meta-Anal. Sep 18, 2024; 12(3): 97210
Published online Sep 18, 2024. doi: 10.13105/wjma.v12.i3.97210
Published online Sep 18, 2024. doi: 10.13105/wjma.v12.i3.97210
Table 3 Role of intestinal ultrasound in predicting response to therapy in ulcerative colitis
Ref. | Study type | Number of patients | Treatment agent(s) | IUS predictor(s) | Follow-up duration | Time points of IUS | Therapeutic outcomes |
Dubbins[25] | Retrospective | 9 UC (19 CD) | Steroid ± immunosuppressive therapy | BWT | 2-4 mo | Baseline, 2-4 mo | No significant change in BWT in UC but there was significant response in CD |
Maconi et al[38] | Prospective | 30 active UC | Steroids | BWT | 2 mo | Baseline and 2 mo | Significant reduction in BWT in clinical responders; IUS response significantly correlated with clinical biochemical and endoscopic activity |
Yoshida et al[26] | Prospective | 26 UC | Cytaphresis + conventional therapy | BWT | 1 year | Baseline and 2-3 wk | Early IUS response (decrease in BWT by 2.5 mm at 2-3 wk) predicted 1 year response (91% vs 40%) lower relapse (9% vs 47%) |
Goertz et al[27] | Prospective | 7 UC | Vedolizumab | BWT, CDS, CEUS- amplitude and time derived parameters | 14 wk | Baseline, 14 wk | Decrease in CDS intensity. Decrease in amplitude dependent CEUS parameters (peak enhancement and wash in rates) |
Maaser et al[28] | Prospective, multi centre | 224 UC | Steroid, anti-TNF, anti-integrin, AZA/6-MP | BWT, BWS, CDS, haustration, lymph nodes, inflammatory fat, ascites | 16 wk | Baseline, 2, 6, and 12 wk | Significant improvement in IUS parameters was seen as early as 2 wk. Significant correlation of normalisation of BWT at 12 wk with clinical improvement and biomarkers |
Les et al[29] | Prospective | 28 UC (89 CD) | 5-ASA, budesonide, AZA, anti-TNF | BWT, BWS, CDS, i-fat, lymph nodes | 6 mo | Baseline | Predictors (overall IBD); immediate treatment escalation (31.7%) Score = 1/[1 + Exp |
Smith et al[30] | Retrospective | 23 CD, 8 UC (22 CD and 7 UC on biologics) | Anti-TNF, ustekinumab, vedolizumab | BWT, CDS | 46 wk | 2, 6, and 14 wk | 16% improvement in BWT at 6 wk and 10% improvement at wk 14 predicted treatment persistence/response at 46 wk |
Vaughan et al[31] | Prospective | 79 UC and 24 CD | Maintenance infliximab | BWT, CDS | Cross-sectional (median disease duration 8 years) | Cross-sectional data | Lower infliximab trough level was associated with higher CDS in both UC and CD |
Helwig et al[32] | Post-hoc analysis of prospective, multi centre studies | 131 UC (118 CD) | Standard of care | BWT, CDS, BWS, i-fat, transmural healing, transmural response | 52 wk | 0, 12, 52 wk | 76.6% TR and 45%-61.4% TH at 12 wk after treatment intensification |
de Voogd et al[33] | Longitudinal, prospective | 30 UC on tofacinib | Tofacitinib | BWT | 8 wk | Baseline and 8 wk | Most accurate BWT cut-off for endoscopic remission was 2.8 mm; for endoscopic response: 3.9 mm and > 32% decrease in BWT |
Ilvemark et al[34] | Blinded, prospective multi centre, observational | 56 acute severe UC | IV steroid | BWT | 48 h and 6 d | Baseline, 48 ± 24 h and 6 ± 1 d | ≤ 20% reduction in BWT has 84.2% sensitivity and 78.4% specificity for determining non-response (AUC: 0.85) |
Allocca et al[19] | Prospective | 49 UC | Infliximab, adalimumab, vedolizumab, ustekinumab | Milan ultrasound criteria based on BWT and CDS intensity | 1 year | Baseline, week 12, and 1 year | MUC ≤ 6.2 at week 12 independent predictor of MES ≤ 1; A ≥ 2 reduction in MUC predicted MES = 0 |
de Voogd et al[33] | Prospective, single center | 51 UC patients | Steroids, 5-ASA, thiopurines, biologics, tofacitinib, cyclosporin | BWT, CDS, haustrations, BWS, fat wrapping, lymph nodes | 26 wk | Baseline, week 2, week 6, weeks 8-26 | BWT and CDS at weeks 2 and 6 predicted endoscopic remission and response at 8-26 wk |
- Citation: Pal P, Mateen MA, Pooja K, Rajadurai N, Gupta R, Tandan M, Duvvuru NR. Role of intestinal ultrasound in ulcerative colitis: A systematic review. World J Meta-Anal 2024; 12(3): 97210
- URL: https://www.wjgnet.com/2308-3840/full/v12/i3/97210.htm
- DOI: https://dx.doi.org/10.13105/wjma.v12.i3.97210